

AAMC Standardized Immunization Form

Last Name:	First Name:	Middle Initial:
DOB:	Street Address:	
Medical School:	City:	
Cell Phone:	State:	
Primary Email:	ZIP Code:	
AAMC ID:		

MMR (Measles, Mumps, Rubella) – 2 doses of MMR vaccine or two (2) doses of Measles, two (2) doses of Mumps and (1) dose of Rubella; or serologic proof of immunity for Measles, Mumps and/or Rubella. Choose only one option. Note: a 3 rd dose of MMR vaccine may be advised during regional outbreaks of measles or mumps if original MMR vaccination was received in childhood.					Copy Attached
Option1	Vaccine	Date			
MMR	MMR Dose #1				
-2 doses of MMR vaccine	MMR Dose #2				
Option 2	Vaccine or Test	Date			
Measles	Measles Vaccine Dose #1		Se	erology Results	
-2 doses of vaccine or positive serology	Measles Vaccine Dose #2		Qualitative Titer Results:	Positive Negative	
	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml	
	Mumps Vaccine Dose #1		Se	erology Results	
Mumps -2 doses of vaccine or positive serology	Mumps Vaccine Dose #2		Qualitative Titer Results:	Positive D Negative	
	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml	
			Serology Results		
Rubella -1 dose of vaccine or	Rubella Vaccine		Qualitative Titer Results:	Positive Negative	
positive serology	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml	
Tetanus-diphtheria-per	tussis — 1 dose of adult Tdap; if last Tdap is more th	an 10 years old, provide	date of last	Td or Tdap booster	
	Tdap Vaccine (Adacel, Boostrix, etc)				
	Td Vaccine or Tdap Vaccine booster (if more than 10 years since last Tdap)		-		
Varicella (Chicken Pox) - 2 doses of varicella vaccine or positive serolog	<i>ay</i>			
	Varicella Vaccine #1		Serology Results		
	Varicella Vaccine #2		Qualitative Titer Results:	Positive D Negative	
	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/mI	
Influenza Vaccine 1 dose annually each fall					
		Date			
	Flu Vaccine				



AAMC Standardized Immunization Form

Name: _

(Last, First, Middle Initial)

_ Date of Birth: _

(mm/dd/yyyy)

-					
Hepatitis B Vaccination 3 doses of Engerix-B, Recombivax or Twinrix or 2 doses of Heplisav-B followed by a <u>QUANTITATIVE</u> Hepatitis B Surface Antibody (titer) preferably drawn 4-8 weeks after the last dose. If negative titer (<10 IU/ml) complete a second Hepatitis B series followed by a repeat titer. If Hepatitis B Surface Antibody titer is negative after a secondary series, additional testing including Hepatitis B Surface Antigen should be performed. See: <u>http://www.cdc.gov/mmwr/pdf/rr/r6210.pdf</u> for more information. Documentation of Chronic Active Hepatitis B is for rotation assignments and counseling purposes only.					
	3-dose vaccines (Engerix-B, Recombivax, Twinrix) or 2-dose vaccine (Heplisav-B)	3 Dose Series	2 Dose Series		
Primary Hepatitis B Series	Hepatitis B Vaccine Dose #1				
- Heplisav-B only requires two doses of vaccine	Hepatitis B Vaccine Dose #2				
followed by antibody testing	Hepatitis B Vaccine Dose #3				
	QUANTITATIVE Hep B Surface Antibody		IU/ml		
Secondary		3 Dose Series	2 Dose Series		
Hepatitis B Series	Hepatitis B Vaccine Dose #4				
<u>Only If no response</u> <u>to primary series</u>	Hepatitis B Vaccine Dose #5				
Heplisav-B only requires two doses of vaccine followed by antibody	Hepatitis B Vaccine Dose #6				
testing	QUANTITATIVE Hep B Surface Antibody		IU/ml		
Hepatitis B Vaccine Non-responder	Hepatitis B Surface Antigen		D Positive D Nega	tive	
(If Hepatitis B Surface Antibody Negative after Primary and Secondary Series)	Hepatitis B Core Antibody		D Positive D Nega	tive	
Chronic Active	Hepatitis B Surface Antigen		D Positive D Nega	tive	
Hepatitis B	Hepatitis B Viral Load		copies/ml		
Additional Vaccines					
Some states and institutions may have additional vaccine requirements for students, health sciences personnel, and first responders depending upon assignment, school requirements or state law. Examples include meningitis vaccine which is mandated in some states for incoming students.					
Vaccination			Date		
Meningococcal Vaccine	e ACWY				
Additional Comments					



AAMC Standardized Immunization Form

Name				Date of Birth:			
	(Last, First, Middle Initial)				(mm/dd/yyyy)		
	CDC Recommendations: Preplacement (baseline) TUBERCULOSIS SCREENING AND TESTING of all health care personnel/ trainees consists of a TB symptom evaluation, a TB test (IGRA or TST), and an individual TB risk asses You only need to complete ONE section below: A or B or C. Section A: If you do not have a history of TB disease or LTBI (Latent Tuberculosis Infection), the results of a 2-step TST (Tuberculosis Skin Test), or TB IGRA (Interferon Gamma Release Assay) blood test are required, <u>regardless</u> of your prior status. You should also check off the results of your individual baseline TB symptom evaluation and TB risk assessment questionnaire. Section B: If you have a history of a positive TST (PPD)≥10mm or a positive IGRA, please supply information regarding fur medical evaluation and treatment below. Section C: History of active tuberculosis, diagnosis and treatment. <u>Health Care Personnel with a baseline NEGATIVE Skin Test result or a NEGATIVE IGRA blood test and</u> <u>negative symptom evaluation will receive annual TB education; additional TB screening may be recommended by</u> <u>local health departments for certain occupational high risk groups.</u>					T ior BCG ırther	
			Tubercul	osis Screening H	listory		
	Section A		Date Placed	Date Read	Result	Interpretation	Copy Attached
Σ		TST step #1			mm	🗅 Pos 🗅 Neg 🗅 Equiv	
sto	No history of	TST step #2			mm	🗅 Pos 🗅 Neg 🗅 Equiv	
P i	prior TB Disease or LTBI			Date	Result		
your history	Dates of the last 2-step TST or TB IGRA blood test are required	QuantiFERON TB (Interferon Gamma Relea			Negative Indeterminate		
on y	(IGRAs include QuantiFERON TB Gold Test, QuantiFERON TB (Interferon Gamma R			Negative Indeterminate		Indeterminate	
	<u>Gold in-tube test, or T-spot</u> <u>TB Test)</u>	Individual TB Sym Assessment	ptom		Negative	Positive (Medical follow-up needed)	
based		Individual TB Risk	Assessment		Negative	Positive (Increased risk TB infection)	
o l	Section B		Date Placed	Date Read	Result		
section		Positive TST			mm		
se	History of			Date	Result		
18	LTBI, Positive TB Skin	QuantiFERON TB (Interferon Gamma Relea	Gold or T-Spot se Assay)		Positive	Negative D Indeterminate	
one	Test, or Positive TB IGRA Blood Test	Chest X-ray					
	(IGRAs include	Treated for latent TB?		🗆 Yes 🗖 No			
complete only	QuantiFERON TB Gold Test, QuantiFERON TB Gold in-tube test, or T-spot TB Test)	If treated for latent TB, list medications taken:					
let		Total Duration of treatment latent TB?		Months			
du	Date of Last A		nual TB Symptom Questionnaire				
se cor	Section C			Date			
				Date of Diagnosis			
Please	History of Active	Date of Treatment Completed					
ľ	Tuberculosis	Date of La	st Annual TB Symp	tom Questionnaire			
			Date o	f Last Chest X-ray			



Name:

(Last, First, Middle Initial)

Date of Birth:

(mm/dd/yyyy)

MUST BE COMPLETED BY YOUR HEALTH CARE PROVIDER OR INSTITUTIONAL DESIGNEE:

Authorized Signature:		Date:		
Printed Name:		Office Use Only		
Title:		Onice Ose Only		
Address Line 1:				
Address Line 2:				
City:				
State:				
Zip:				
Phone:	() Ext:			
Fax:	()			
Email Contact:				

*Sources:

- 1. Kim DK, Hunter P. Advisory Committee on Immunization Practices: Recommended Immunization Schedule for Adults Aged 19 years or Older—United States, 2019. MMWR 2019; 68:115-118. <u>http://dx.doi.org/10.15585/mmwr.mm6805a5</u>.
- 2. Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR 2011, Vol 60(RR077):1-45
- 3. Schillie S, Harris A, Link-Gelles R. et al. Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant. MMWR 2018;67;455-8. <u>https://doi.org/10.15585/mmwr.mm6715a5</u>.
- 4. Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR 2019;68:439-443. <u>https://www.cdc.gov/mmwr/volumes/68/wr/mm6819a3.htm</u>.
- 5. Centers for Disease Control and Prevention. Tuberculosis (TB) Screening, Testing, and Treatment of U.S. Health Care Personnel Frequently Asked Questions (FAQs). <u>https://www.cdc.gov/tb/topic/infectioncontrol/healthcarepersonnel-faq.htm</u>.